174 related articles for article (PubMed ID: 22218118)
1. Angiotensin receptor blocker and N-acetyl cysteine for reduction of proteinuria in patients with type 2 diabetes mellitus.
Rasi Hashemi S; Noshad H; Tabrizi A; Mobasseri M; Tayebi Khosroshahi H; Heydarnejad M; Khalaj MR; Aghamohammadzadeh N
Iran J Kidney Dis; 2012 Jan; 6(1):39-43. PubMed ID: 22218118
[TBL] [Abstract][Full Text] [Related]
2. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL.
de Zeeuw D; Remuzzi G; Parving HH; Keane WF; Zhang Z; Shahinfar S; Snapinn S; Cooper ME; Mitch WE; Brenner BM
Kidney Int; 2004 Jun; 65(6):2309-20. PubMed ID: 15149345
[TBL] [Abstract][Full Text] [Related]
3. Losartan in diabetic nephropathy.
Perico N; Ruggenenti P; Remuzzi G
Expert Rev Cardiovasc Ther; 2004 Jul; 2(4):473-83. PubMed ID: 15225108
[TBL] [Abstract][Full Text] [Related]
4. Adiponectin is positively associated with insulin resistance in subjects with type 2 diabetic nephropathy and effects of angiotensin II type 1 receptor blocker losartan.
Guo LL; Pan Y; Jin HM
Nephrol Dial Transplant; 2009 Jun; 24(6):1876-83. PubMed ID: 19164322
[TBL] [Abstract][Full Text] [Related]
5. Additive antiproteinuric effect of pentoxifylline in patients with type 2 diabetes under angiotensin II receptor blockade: a short-term, randomized, controlled trial.
Navarro JF; Mora C; Muros M; GarcĂa J
J Am Soc Nephrol; 2005 Jul; 16(7):2119-26. PubMed ID: 15917336
[TBL] [Abstract][Full Text] [Related]
6. Effect of addition of silymarin to renin-angiotensin system inhibitors on proteinuria in type 2 diabetic patients with overt nephropathy: a randomized, double-blind, placebo-controlled trial.
Fallahzadeh MK; Dormanesh B; Sagheb MM; Roozbeh J; Vessal G; Pakfetrat M; Daneshbod Y; Kamali-Sarvestani E; Lankarani KB
Am J Kidney Dis; 2012 Dec; 60(6):896-903. PubMed ID: 22770926
[TBL] [Abstract][Full Text] [Related]
7. Low-dose angiotensin II receptor antagonists and angiotensin II-converting enzyme inhibitors alone or in combination for treatment of primary glomerulonephritis.
Renke M; Tylicki L; Rutkowski P; Rutkowski B
Scand J Urol Nephrol; 2004; 38(5):427-33. PubMed ID: 15764256
[TBL] [Abstract][Full Text] [Related]
8. Importance of baseline distribution of proteinuria in renal outcomes trials: lessons from the reduction of endpoints in NIDDM with the angiotensin II antagonist losartan (RENAAL) study.
Zhang Z; Shahinfar S; Keane WF; Ramjit D; Dickson TZ; Gleim GW; Mogensen CE; de Zeeuw D; Brenner BM; Snapinn SM
J Am Soc Nephrol; 2005 Jun; 16(6):1775-80. PubMed ID: 15872078
[TBL] [Abstract][Full Text] [Related]
9. Aldosterone synthase (CYP11B2)-344T/C polymorphism and renoprotective response to losartan treatment in diabetic nephropathy.
Schjoedt KJ; Lajer M; Andersen S; Tarnow L; Rossing P; Parving HH
Scand J Clin Lab Invest; 2006; 66(3):173-80. PubMed ID: 16714246
[TBL] [Abstract][Full Text] [Related]
10. [Effect of losartan on renal and cardiovascular complications of patients with type 2 diabetes and nephropathy].
Parving HH; Brenner BM; Cooper ME; de Zeeuw D; Keane WF; Mitch WE; Remuzzi G; Snapinn SM; Zhang Z; Shahinfar S
Ugeskr Laeger; 2001 Oct; 163(40):5514-9. PubMed ID: 11601117
[TBL] [Abstract][Full Text] [Related]
11. Recent advances in management of type 2 diabetes and nephropathy: lessons from the RENAAL study.
Keane WF; Lyle PA;
Am J Kidney Dis; 2003 Mar; 41(3 Suppl 1):S22-5. PubMed ID: 12612946
[TBL] [Abstract][Full Text] [Related]
12. Use of losartan in reducing microalbuminuria in normotensive patients with type-2 diabetes mellitus.
Agha A; Bashir K; Anwar E
Nepal Med Coll J; 2007 Jun; 9(2):79-83. PubMed ID: 17899953
[TBL] [Abstract][Full Text] [Related]
13. Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial.
Eijkelkamp WB; Zhang Z; Remuzzi G; Parving HH; Cooper ME; Keane WF; Shahinfar S; Gleim GW; Weir MR; Brenner BM; de Zeeuw D
J Am Soc Nephrol; 2007 May; 18(5):1540-6. PubMed ID: 17409317
[TBL] [Abstract][Full Text] [Related]
14. Reduction of microalbuminuria by using losartan in normotensive patients with type 2 diabetes mellitus: A randomized controlled trial.
Agha A; Amer W; Anwar E; Bashir K
Saudi J Kidney Dis Transpl; 2009 May; 20(3):429-35. PubMed ID: 19414946
[TBL] [Abstract][Full Text] [Related]
15. Spironolactone in type 2 diabetic nephropathy: Effects on proteinuria, blood pressure and renal function.
van den Meiracker AH; Baggen RG; Pauli S; Lindemans A; Vulto AG; Poldermans D; Boomsma F
J Hypertens; 2006 Nov; 24(11):2285-92. PubMed ID: 17053552
[TBL] [Abstract][Full Text] [Related]
16. A renoprotective effect of low dose losartan in patients with type 2 diabetes.
Sawaki H; Terasaki J; Fujita A; Nakagawa S; Kanatsuna N; Sadahiro K; Isotani H; Imagawa A; Hanafusa T
Diabetes Res Clin Pract; 2008 Jan; 79(1):86-90. PubMed ID: 17889959
[TBL] [Abstract][Full Text] [Related]
17. [Risk and prevention of diabetic nephropathy].
Ravera M; Re M; Deferrari G
G Ital Nefrol; 2007; 24 Suppl 38():13-9. PubMed ID: 17922442
[TBL] [Abstract][Full Text] [Related]
18. Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy.
de Zeeuw D; Remuzzi G; Parving HH; Keane WF; Zhang Z; Shahinfar S; Snapinn S; Cooper ME; Mitch WE; Brenner BM
Circulation; 2004 Aug; 110(8):921-7. PubMed ID: 15302780
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of angiotensin II receptor blockade in elderly patients with diabetes.
Winkelmayer WC; Zhang Z; Shahinfar S; Cooper ME; Avorn J; Brenner BM
Diabetes Care; 2006 Oct; 29(10):2210-7. PubMed ID: 17003295
[TBL] [Abstract][Full Text] [Related]
20. Additive antioxidative effects of azelnidipine on angiotensin receptor blocker olmesartan treatment for type 2 diabetic patients with albuminuria.
Abe M; Maruyama N; Okada K; Matsumoto S; Matsumoto K; Soma M
Hypertens Res; 2011 Aug; 34(8):935-41. PubMed ID: 21654755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]